(Sharecast News) - Shares in Novartis tanked on Tuesday, with the stock on track for its worst daily performance on record, after disappointing results from a clinical trial of its muscle-wasting disease treatment.
The news adds further pressure to the Swiss pharma giant's pipeline following another clinical setback announced the day...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE